Needham Maintains Buy on Autolus Therapeutics, Raises Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reaffirmed a Buy rating on Autolus Therapeutics (NASDAQ:AUTL) and increased the price target from $7 to $8.
January 22, 2024 | 6:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum maintains a Buy rating on Autolus Therapeutics and raises the price target from $7 to $8.
The reaffirmation of a Buy rating coupled with an increased price target typically signals analyst confidence in the company's future performance, which can positively influence investor sentiment and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100